Healthy
Conditions
Brief summary
Study to compare the bioavailability of Lacidipine and Telmisartan administered as fixed dose combination tablets with the separate Telmisartan and Lacidipine tablets.
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and female Caucasian subjects as determined by results of screening * Age ≥ 18 and ≤ 50 years * Broca ≥ - 20 % and ≤ + 20 % * Written informed consent in accordance with Good Clinical Practice and local legislation given
Exclusion criteria
* Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of gastrointestinal tract (except appendectomy) * Disease of the central nervous system (such as epilepsy) or psychiatric disorders or neurologic disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) (≤ 1 month prior to administration or during the trial, except for oral contraceptives) * Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial except for oral contraceptives) * Participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial) * Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (\> 60 g/day) * Blood donation \> 100 ml (≤ 4 weeks prior to administration or during the trial) * Excessive physical activities (≤ 10 days prior to administration or during the trial) * Any laboratory value outside the reference range of clinical relevance * Females only: * no reliable contraception (e.g. oral contraceptives, 3-month injection, intrauterine device, sterilisation) * pregnancy of breast feeding period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the curve at steady state (AUCss) | up to 72 hours after drug administration at day 7 |
| Maximum concentration (Cmax,ss) | up to 72 hours after drug administration at day 7 |
| Time to maximum concentration (tmax) | up to 72 hours after drug administration at day 7 |
| Total apparent clearance (CLtot/f) | up to 72 hours after drug administration at day 7 |
| Apparent volume of distribution (Vz/f) | up to 72 hours after drug administration at day 7 |
| Mean residence time (MRTss) | up to 72 hours after drug administration at day 7 |
| Terminal half-life (t1/2) | up to 72 hours after drug administration at day 7 |
| Number of patients with adverse events | up to 66 days |
| Number of patients with abnormal findings in physical examination | up to 66 days |
| Number of patients with clinically relevant changes in electrocardiogram | up to 66 days |
| Number of patients with clinically relevant changes in vital signs | up to 66 days |
| Number of patients with abnormal changes in laboratory parameters | up to 66 days |
| Assessment of tolerability on a verbal rating scale | between day 3 and 5 after last study drug administration |
Outcome results
None listed